All News

The phase 3 DESTINY-Lung04 trial met its main goal of keeping cancer from growing longer than chemotherapy plus immunotherapy did.

After reading another cancer survivor’s story, Sue McCarthy reflects on her own experience with guilt, her stage 3B lung cancer diagnosis and how helping others through a cancer support group helped her find confidence and purpose.

Cara Curcio’s melanoma journey changed her life as a wife and mother, but treatment, family and hope have kept her moving forward.

Nicole Schultz was treated for acute myeloid leukemia as a teenager. Two decades later, chronic graft-versus-host disease and ongoing survivorship monitoring remain part of her care.

A gynecologic oncologist on the testing that shapes treatment, the side effect not to push through and why fertility questions can't wait.

Sixteen years after treatment, cancer fatigue is still my constant shadow. I can't cure it, so I've learned to manage it instead of letting it manage me.

Dr. Priscilla Merriam discusses why sarcoma is often mistaken for a benign growth, how treatment differs across more than 150 types and where patients can find expert care.

The FDA granted accelerated approval to Zenbexus with daratumumab and hyaluronidase-fihj and dexamethasone for previously treated multiple myeloma.

Sixteen years after my own cancer journey, I find myself reflecting on the lasting shadows of cancer and the connection survivors can offer one another.

Black women with ovarian cancer had a 45% higher risk of death than White women, with the gap widest in high-vulnerability neighborhoods.

Krystal Player-Jackson, oncology nurse of Ochsner LSU Shreveport, continued caring for cancer patients with compassion and resilience even while losing her father and brother to cancer weeks apart.

Nicole Schulz was 14 when she received an AML diagnosis. She shares what carried her through two transplants and 11 months in the hospital.

Adding sirexatamab did not delay cancer growth overall, but patients with higher levels of a blood protein called DKK1 went longer without their cancer worsening.

Laura Yeager reflects on attending a Bridgerton-themed gala as a flat-chested breast cancer survivor, finding humor and freedom in a room full of corsets and cleavage.

A multiple myeloma survivor and advocate answers the questions people ask most after a diagnosis, from maintenance therapy to stem cell transplant.

Weekly smartphone check-ins that alerted the care team when symptoms worsened and improved physical functioning at six months.

Divesiran met the primary end point of the phase 2 SANRECO trial, with 88% of patients avoiding phlebotomy and keeping hematocrit below 45%, according to new trial results.

Doctors say patients with cancer face distinct risks during the cyclosporiasis outbreak that spans 45 states.

After moving two hours away, a survivor weighs staying with the cancer center that knows her history against finding an oncologist close to home.

Sanita Burgic, of Washington University Siteman Cancer Center, combines clinical excellence and deep empathy to support cancer patients and elevate her entire oncology team.

Dr. Priscilla Merriam discusses how sarcomas can be mistaken for benign growths like lipomas and fibroids, and why asking about a biopsy can matter before surgery.

Lung cancer advocate Katie shares how losing her father to the disease and her own cancer journey inspire her work with LiveLung today.

Multiple myeloma and breast cancer survivor Valerie Traynham shares why survivorship begins at diagnosis and offers hope, resilience and life after cancer insights.

An oncologist explains why the choice between removing one lobe or the whole thyroid should be a conversation, not a surprise.

Noreen Walsh, RN, MSN, OCN, of St. Francis Hospital and Cancer Institute, builds deep personal bonds with cancer patients and families that extend far beyond clinical care.

Dr. Robert S. Alter discusses what to ask before thyroid surgery, why "active surveillance" isn't passive and how targeted therapy is changing outcomes.

At least half of patients get nervous before a follow-up scan. Dr. Geoffrey Pelz explains why that is common, what he wants patients to hear at the first visit and how much lung cancer treatment has shifted in 15 years.

FDA approves Tudriqev plus Opdivo for adults with advanced melanoma that progressed after PD-1 immunotherapy, expanding treatment options.